| Date | Time | Source | Headline | Symbol | Company |
| 05/22/2024 | 8:00AM | GlobeNewswire Inc. | First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/20/2024 | 4:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/20/2024 | 6:00AM | GlobeNewswire Inc. | Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/17/2024 | 3:08PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/14/2024 | 8:00AM | GlobeNewswire Inc. | Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/10/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/08/2024 | 4:31PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/07/2024 | 8:50AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/07/2024 | 7:29AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 05/07/2024 | 6:00AM | GlobeNewswire Inc. | Esperion Reports First Quarter 2024 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 04/29/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Participate in Upcoming May Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 04/23/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Report First Quarter 2024 Financial Results on May 7 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 04/07/2024 | 2:45PM | GlobeNewswire Inc. | Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 04/01/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/26/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/25/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/22/2024 | 6:26PM | Business Wire | U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/22/2024 | 3:10PM | GlobeNewswire Inc. | U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 03/22/2024 | 11:04AM | GlobeNewswire Inc. | CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/27/2024 | 9:19AM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/27/2024 | 7:23AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/27/2024 | 6:00AM | GlobeNewswire Inc. | Esperion Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/16/2024 | 4:30PM | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/14/2024 | 2:14PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/14/2024 | 10:50AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/14/2024 | 8:42AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/14/2024 | 6:11AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/13/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 02/01/2024 | 2:00PM | GlobeNewswire Inc. | RFK, Esperion Therapeutics Announce 2024 Promotional Schedule | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 01/23/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares | NASDAQ:ESPR | Esperion Therapeutics Inc |